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This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e159. Learning Objective–Upon
completion of this activity, successful learners will be able to identify the risk for developing colorectal cancer (CRC) related to the type of family
history; identify the absolute risk for developing colorectal cancer for individuals with at least one first degree relative (FDR) with CRC younger
than 50 years; and define “familial colorectal cancer.”BACKGROUND & AIMS: Guidelines recommend that individuals with familial colorectal cancer undergo colonoscopy
surveillance instead of average-risk screening. However, these recommendations vary widely.
To substantiate appropriate surveillance strategies, precise and valid evidence-based risk es-
timates are needed for individuals with a family history of colorectal cancer (CRC).METHODS: We systematically searched MEDLINE, EMBASE, and Cochrane from inception to July 2018 for
case–control and cohort studies investigating the effect of family history on CRC risk. We
calculated summary estimates of pooled relative risks (RRs) using a random-effects model. Life
tables were created to convert RR estimates into absolute risk estimates.RESULTS: We screened 4417 articles and identified 42 eligible case–control and 20 cohort studies. In
case–control studies, the RR for CRC in patients with 1 first-degree relative (FDR with CRC) was
1.92 (95% CI, 1.53–2.41) and 1.37 (95% CI, 0.76–2.46) for cohort studies. For individuals with 2
or more FDRs with CRC, the RR was 2.81 in case–control studies (95% CI, 1.73–4.55) and 2.40 in
cohort studies (95% CI, 1.76–3.28). For individuals having a FDR diagnosed with CRC at an age
younger than 50 years, the RR for CRC in their FDRs was 3.57 in case–control studies (95% CI,
1.07–11.85) and 3.26 in cohort studies (95% CI, 2.82–3.77). The cumulative absolute risks for
CRC at 85 years in Western Europe were 4.8% for persons with 1 FDR with CRC (95% CI, 2.7%–
8.3%), 8.2% for individuals with 2 or more FDRs (95% CI, 6.1%–10.9%), and 11% for persons
with a FDR diagnosed with CRC at an age younger than 50 years (95% CI, 9.5%–12.4%).CONCLUSIONS: In this systematic review andmeta-analysis, we found that the RRof CRC among FDRs is lower than
previously expected, especially based on cohort studies. Risk estimates are affected by the number
of relatives with CRC and their age at diagnosis. Intensified colonoscopy surveillance strategies
could be considered for high-risk groups. PROSPERO trial identification no: CRD42018103058.Keywords: Colon Cancer; Risk Factors; Detection; Family History.aAuthors share co-first authorship. bAuthors share co-senior authorship.
Abbreviations used in this paper: AR, absolute risk; CRC, colorectal
cancer; FCC, familial colorectal cancer; FDR, first-degree relative; FH,
family history; FIT, fecal immunochemical testing; RR, relative risk; SDR,
second-degree relative; TDR, third-degree relative.
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https://doi.org/10.1016/j.cgh.2019.09.007Colorectal cancer (CRC) is the third most incidentcancer and the second leading cause of cancer-
related deaths.1 Although the majority of CRC is
sporadic, twin studies have shown that up to 30% of
patients with CRC harbor a familial component.2 How-
ever, in only 3% to 6% of all CRC cases has a genetic
cause been elucidated by identification of mutations in
the APC gene, MuTYH gene, and in the mismatch repair
genes, among other less-common mutations.2
What You Need to Know
Background
To determine appropriate surveillance strategies,
precise and valid evidence-based risk estimates are
needed for individuals with a family history of
colorectal cancer (CRC).
Findings
In a systematic review and meta-analysis, we found
that the relative risk of CRC in individuals with 1
first-degree relative (FDR) was not even double that
of persons with no relatives with CRC. Risk was
higher for persons with 2 or more FDRs with CRC or
with a FDR who was diagnosed with CRC at younger
than age 50 years.
Implications for patient care
Colonoscopy surveillance strategies should be
intensified for persons with a high risk of CRC based
on family history of CRC.
2658 Roos et al Clinical Gastroenterology and Hepatology Vol. 17, No. 13Familial colorectal cancer (FCC) is defined as the
remaining heterogeneous group of individuals carrying
an increased familial risk for developing CRC without
harboring a known genetic cause. For individuals with
family members with CRC, the risk of developing CRC
depends on various factors, such as the degree or num-
ber of family members affected, or the age at diagnosis of
CRC.3 A recent systematic review and meta-analysis
showed that the relative risk (RR) in first-degree
relatives (FDRs) of developing CRC was lower than
previously reported.4 Data on the anticipated risk for
second-degree relatives (SDRs) and third-degree rela-
tives (TDRs) were not reported. Furthermore, data on
case–control and cohort studies were combined and es-
timates of absolute risk (AR) for CRC were lacking,
although important when informing individuals about
their risk.
According to various clinical practice guidelines, in-
dividuals with FCC are recommended to undergo more
intensive surveillance strategies than the general popu-
lation, starting at an earlier age.5–8 However, the defini-
tion of who should undergo intensified colonoscopy
surveillance instead of average-risk screening varies
widely.
For individuals who have a family history (FH) of
CRC, evidence-based estimates of the RR and AR of
developing CRC are needed to decide which patients
need more intensive colonoscopy surveillance. Through a
systematic review and meta-analysis we wanted to
obtain summary estimates of the risk of developing CRC
in asymptomatic individuals with a FH of CRC not un-
dergoing surveillance, compared with the general popu-
lation, and of the AR of developing CRC.
Methods
This systematic review and meta-analysis was per-
formed in accordance with the PRISMA guidelines.9 The
protocol was registered prospectively at PROSPERO
(CRD42018103058).
Search Strategy for Study Identification
Ovid MEDLINE, Ovid EMBASE, and Cochrane were
searched for eligible studies from inception to July 2018.
The search strategy included 3 main term categories: fam-
ily, colorectal neoplasm, and risk (Supplementary Appendix
1). No language, publication date, or publication status re-
strictions were imposed. References cited in selected arti-
cles and relatedmeta-analyseswere searched for additional
eligible studies, referred to as cross-references.
Study Selection and Data Extraction
Three reviewers (C.M.-S., V.H.R., and L.M.-P.) inde-
pendently screened all titles and abstracts. Disagreement
between reviewers was solved by consensus. Afterselection of articles fulfilling the eligibility criteria, data
extraction was performed independently by 1 of the 3
reviewers. The data extraction sheet consisted of the
following: (1) characteristics of study participants; (2)
type of FH: number, degree, and age at diagnosis of each
family member with CRC; (3) comparator group; and (4)
type of outcome measure. Data extraction was checked
by 1 of the 2 other reviewers (C.M.-S. or V.H.R.).
Study Types
Case–control and cohort studies investigating the ef-
fect of a FH of CRC on the risk of developing CRC and
reporting incidence data were included. A positive FH
was defined as having any type of FH of CRC. Studies
were included when the risk of developing CRC in adults
with family members affected with CRC (18 y) was
compared with adults not having a FH of CRC.
Studies were excluded if subjects were recruited from
colonoscopy surveillance programs (because surveil-
lance decreases the risk of developing CRC), if controls
had other malignant conditions, if results were based on
mortality data alone, and if information about the type of
FH or type of cancer was ill-defined or restricted. When
multiple studies reported outcomes retrieved from the
same population, only 1 study was selected, either the
most applicable to our research question or the study
reporting the most recent data.Risk of Bias Assessment
The risk of bias was assessed independently by 2 re-
viewers (C.M.-S. and V.H.R.) using the Quality in Prognosis
Studies tool.10 Quality was analyzed based on 6 domains:
December 2019 Family History and Colorectal Cancer Risk 2659study participation; study attrition; prognostic factor
measurement; outcome measurement; study confound-
ing; and statistical analysis and reporting. Finally, studies
were classified as either high quality or low quality.Statistical Analysis
In case–control studies, the odds ratio or observed vs
expected ratios were calculated. For cohort studies, esti-
mates of RR and corresponding 95% CIs were calculated
from extracted data. When crude numbers were not
available, an unadjusted summary estimate was used.
Odds ratios and observed vs expected ratios were
considered a good estimate of the RR because the preva-
lence of CRC among asymptomatic subjects is considered
to be low.11 When hazard ratios were reported in cohort
studies, these were considered estimates of the RR.
Because data were assumed to be heterogeneous, a
random-effects meta-analysis using the generic inverse-
variance weighting method was used to obtain summary
estimates. To reduce heterogeneity, a stratified meta-
analysis was performed using the following subgroups:
number of FDRs affected (1 FDR, 1 FDR, and 2 FDRs);
1 SDRs, 1 TDRs, and age at diagnosis of the index pa-
tient. Statistical heterogeneity between studies was
assessed using among-study variance (s2) and statistic I2.12
Data for case–control and cohort studies were re-
ported separately because case–control studies were
assumed to be at higher risk of bias. A sensitivity analysis
was performed that included only studies that explicitly
excluded patients with Lynch syndrome.
The possibility of publication bias was assessed by
inspection of funnel plots.12 The meta-analysis was per-
formed using Review Manager version 5.3 (The Nordic-
Cochrane Center, The Cochrane Collaboration, Copenha-
gen, Denmark).
Summary estimates of cohort studies were converted
into AR estimates using the method proposed by Dupont.13
We chose Western Europe and the United States as refer-
ence populations for our AR analysis. Western Europe
represented the following countries: Austria, Belgium,
France, Germany, Luxemburg, The Netherlands, and
Switzerland. The US data were based on the National In-
stitutes of Health and Surveillance, Epidemiology, and End
Results databases. First, baseline cancer and mortality
hazards were obtained with a life-table approach using age-
specific CRC incidence rates of 2018 from Globocan,14 and
the most recent age-specific mortality rates available from
the World Health organization15 (Supplementary Table 1).
Then, under a proportional hazards assumption and
accounting for the competing risk of all-cause mortality,
absolute CRC risk estimates corresponding to specific RRs
were derived (see Appendix I in Dupont13 for technical
details). Namely, we estimated ARs for the general popu-
lation (RR ¼ 1, by definition) for individuals with the
following: 1 affected FDR; at least 1 affected FDR; at least 2
affected FDRs; and at least 1 FDR with CRC diagnosedbefore age 50 or 60 years. The cumulative AR at 85 years of
age was calculated and curves for developing CRC over 10
years were shown graphically. AR data analysis was per-
formed using R version 3.5.1 (RStudio, Inc, Boston, MA).16Results
We identified 7827 articles, of which 4417 articles
remained after deduplication (Figure 1). After exclusion
and addition of cross-references, 160 articles remained for
full-text screening. Of those, a total of 62 articles (42
case–control and 20 cohort studies) fulfilled the eligibility
criteria and were included in this meta-analysis.17–78
Characteristics of selected studies are summarized in
Supplementary Tables 2 and 3. Among these, 23 studies
were conducted in Europe,17,18,20,24–26,29,31,
34,36,37,39,40,42,46,57,59,60,63–65,71,77 18 in the Asia-Pacific
nations,19,23,32,38,45,47,49,50,52,54–56,62,66,70,72,74,76 and 21
in America.21,22,27,28,30,33,35,41,43,44,48,51,53,58,61,67–69,73,75,78
Subjects were enrolled from 1952 until 2014.
Among 42 case–control studies, 23 control groups
were selected from the general population,40–42,44,45,
47–49,53,56,58,59,61,63,64,66,70,72–75,77,78 17 control groups
were hospital-based,37,39,46,50–52,54,55,57,60,62,65,67–69,71,76
1 consisted of patients retrieved from primary care
centers,38 and 1 study had both hospital and population-
based controls.43 Of 20 cohort studies, 11 had a retro-
spective design17,18,20,22–25,27,28,31,34 8 a prospective
design,19,21,26,30,32,33,35,36 and 1 a cross-sectional
design.29 Seventeen studies used a population-
based,17,18,21–29,31–36 2 used a screening-based,19,30 and
1 used a cancer database20 as control groups. In most
case–control and cohort studies the FH was assessed
using questionnaires or registry-based FH data.Risk of Colorectal Cancer According to the
Degree and Number of Family Members
Individuals with at least 1 FDR with CRC (Figure 2)
were 2.22 (95% CI, 2.00–2.48) times more likely to
develop CRC according to 41 case–control stud-
ies37–70,72–78 and 1.67 (95% CI, 1.52–1.82) times more
likely according to 12 cohort studies.17,19,20,26,28–32,34–36
Both case–control and cohort studies showed consider-
able heterogeneity (I2 ¼ 82% and I2 ¼ 100%, respec-
tively). When having only 1 FDR, 8 case-control studies
reported a pooled RR of 1.92 (95% CI,
1.53–2.41),43,50,57,65,72,75–77 and among 3 cohort studies
the pooled RR was 1.37 (95% CI, 0.76–2.46)
(Figure 2).30,32,33 Individuals with at least 2 FDRs with
CRC (Figure 2) were more likely to develop CRC with a
pooled RR of 2.81 (95% CI, 1.73–4.55) among 8
case–control studies,43,50,57,65,72,75–77 and a pooled RR of
2.40 (95% CI, 1.76–3.28) in 3 cohort studies.26,30,32 Both
types of studies showed substantial heterogeneity (I2 ¼
56% and I2 ¼ 74%, respectively).
Figure 1. Flow diagram of study selection. CRC, colorectal cancer.
2660 Roos et al Clinical Gastroenterology and Hepatology Vol. 17, No. 13When having at least 1 SDR with CRC a pooled RR of
1.87 (95% CI, 1.39–2.51) was reported in 8
case–control studies,37,38,49,55,63,72,73,77 and a pooled
RR of 1.09 (95% CI, 1.03–1.15) in 3 cohort studies
(Figure 2).17,28,32
Only 2 case–control studies evaluated the risk of
developing CRC among individuals with at least 1 TDR
with CRC compared with subjects with no FH, showing a
RR of 2.28 (95% CI, 0.48–10.78)38,73 and a lower pooled
RR of 1.05 (95% CI, 1.02–1.08) among 2 cohort
studies.28,32
Inspection of funnel plots both including as well as
excluding Lynch syndrome patients showed asymmetry,
suggesting publication bias. Smaller studies showing lit-
tle or no effect seemed not to have been published
(Supplementary Figure 1).
Sensitivity Analysis
In the sensitivity analysis, excluding Lynch syndrome
patients, slightly higher pooled RRs were found for both
case–control and cohort studies in individuals with at
least 1 FDR. In contrast, for individuals with only 1 FDR
or at least 2 FDRs with CRC, pooled RRs in both types of
studies were lower (Supplementary Figure 2).
Risk of Colorectal Cancer According to Age at
Diagnosis
Because the effect of having at least 1 affected FDR
was more remarkable and robust and data regarding
SDRs and TDRs were limited, we assessed the pooledeffect of the age at diagnosis among FDRs using a
random-effects meta-analysis model.
The meta-analysis showed that having at least 1 FDR
with CRC younger than the age of 50 resulted in a pooled
RR of 3.57 (95% CI, 1.07–11.85) for case–control
studies56,73 and 3.26 (95% CI, 2.82–3.77) for cohort
studies.18,21,26,32 Heterogeneity was substantial in
case–control studies (I2 ¼ 65%) and absent in cohort
studies. In contrast, among studies reporting on the CRC
risk in patients older than age 50, a pooled RR of 1.88
(95% CI, 1.66–2.13)56,73 and 1.83 (95% CI,
1.55–2.16)21,26,32 were obtained, respectively (Figure 3).
When index patients were diagnosed at younger than
60 years of age, the pooled RR for case–control and
cohort studies on the CRC risk were substantially lower:
2.40 (95% CI, 2.12–2.73)57,65,73 and 2.02 (95% CI,
1.59–2.57),18,21,28,30 respectively. Case–control studies
showed no heterogeneity whereas cohort studies
showed substantial heterogeneity (I2 ¼ 73%). The CRC
risk when there was a relative diagnosed at older than
age 60 years was similar to the risk of older than age 50
years for both case–control and cohort studies (pooled
RR, 1.98; 95% CI, 1.56–2.5257,65,73; and pooled RR, 1.60;
95% CI, 1.35–1.9021,28,30,32), respectively (Figure 3).
An inspection of the funnel plot showed no signs of
publication bias (Supplementary Figure 3).Quality Assessment Among Included Studies
Results of the risk of bias assessment are provided in
Supplementary Figures 4 and 5 and explained in
Supplementary Table 4. The risk of bias assessment
Figure 2. Forest plot degree and number of family members
affected. FDR, first-degree relative; SDR, second-degree relative;
TDR, third-degree relative.
December 2019 Family History and Colorectal Cancer Risk 2661showed that especially in case–control studies, baseline
characteristics often were not well described, resulting in
a high risk of bias in study participation. Study attrition,
described as the loss to follow-up evaluation of the study
population, often was not addressed within the studies.
Furthermore, FH assessment often was not verified in
the studies, especially in case–control studies. The
development of CRC among index patients frequently
was confirmed using either pathology reports or medical
records. The majority of studies had adjusted for con-
founding and this was described adequately in the
Methods sections, when it concerned the primary anal-
ysis of the study.Absolute Risk Calculations
The cumulative AR of developing CRC in Western
Europe at the age of 85 years was 3.5% in the general
population, 4.8% (95% CI, 2.7%–8.3%) for those with 1
FDR with CRC, 5.8% (95% CI, 5.3%–6.3%) for those with
at least 1 FDR, and 8.2% (6.1%–10.9%) for those with at
least 2 FDRs. Regarding age at diagnosis, for those with
at least 1 FDR with CRC at younger than age 60 years the
cumulative AR was 6.9% (95% CI, 5.5%–8.7%),
increasing to 11% (95% CI 9.5%–12.4%) for those with
at least 1 FDR at younger than age 50 years (Figure 4A).
The AR of developing CRC in the United States at age 85
years was 2.7% in the general population, 3.6% (95% CI,
2.0%–6.4%) for those with 1 FDR with CRC, 4.4% (95%
CI, 4.0%–4.8%) for those with at least 1 FDR, and 6.2%
(4.6%–8.4%) for those with at least 2 FDRs. Regarding
the age at diagnosis, for those with at least 1 FDR with
CRC at younger than age 60 years the risk of developing
CRC was 5.3% (95% CI, 4.2%–6.7%), increasing to 8.3%
(95% CI, 7.3%–9.5%) for those with at least 1 FDR at
younger than age 50 years (Figure 4B).
The probability of developing CRC in the next 10 years
until age 60 was less than 1% for the general population
and slightly increased to reach a maximum of 1.5% for the
US general population and a maximum of 2% for the
Western Europe general population at 75 years. For all
subgroups of individuals with a positive FH of CRC, the risk
of developing CRC in the coming 10 years was less than
1% until age 40 years, and increased to 1.7% (95% CI,
1.5%–2.0%) in the United States and 1.8% (95% CI, 1.5%–
2.1%) in Western Europe at 50 years for individuals with
at least 1 FDR at younger than age 50 years. The risk of
developing CRC per 10-year period increased to 2.0% to
2.7% (95% CI, 1.1%–3.6% and 1.5%–4.8%) between ages
75 and 85 years for individuals with 1 FDR, 3.5% to 4.7%
(95% CI, 2.6%–4.7% and 3.5%–6.3%) for individuals with
at least 2 FDRs, 2.9% to 4.0% (95% CI, 2.3%–3.7% and
3.1%–5.0%) for persons with at least 1 FDR at younger
than age 60 years, and 4.7% to 6.3% (95% CI, 4.1%–5.4%
and 5.5%–7.2%) for individuals with at least 1 FDR at
younger than age 50 years (Figure 5A and B) for the US
and Western Europe populations, respectively.
Figure 3. Forest plot age at
diagnosis of CRC in FDRs.
FDR, first-degree relative.
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We showed in this systematic review and meta-
analysis that the risk of developing CRC in individuals
with a FH of CRC is lower than previously reported,
especially according to cohort studies.4,79–81 RRs at
least doubled for individuals having at least 1 FDR
with CRC based on case–control studies, and almost
tripled for those with at least 2 FDRs with CRC and
with a FDR diagnosed with CRC before the age of 50
years. Moreover, AR estimates showed that the risk ofdeveloping CRC between 40 and 50 years was low and
gradually increased at the age of 50, providing ratio-
nale for surveillance recommendations from this age
onward. Therefore, we believe intensified surveillance
strategies might be considered starting at age of 50
years. Our RR and AR estimates may be used to iden-
tify the high-risk groups in whom intensified colo-
noscopy surveillance is justified. For those individuals
with a less extensive FH of CRC, average-risk screening
options such as fecal immunochemical testing can be
proposed.
Figure 4. Cumulative absolute risk of developing CRC at 85 years in (A) Western Europe and (B) the United States. FDR, first-
degree relative.
December 2019 Family History and Colorectal Cancer Risk 2663Meta-analyses published between 2001 and 2006
evaluated the risk of developing CRC in individuals with
a positive FH of CRC and reported a pooled RR of having
at least 1 FDR to be more than 2-fold, ranging from 2.24
to 2.26.79–81 A more recent meta-analysis showed lower
RR estimates (RR, 1.76; 95% CI, 1.57–1.97).4 However,
these previously published meta-analyses had some
drawbacks and limitations: summary estimates consisted
of both case–control and cohort studies, none of the
studies except the study by Butterworth et al79Figure 5. Cumulative absolute risk of developing CRC in 10 y
colorectal cancer; FDR, first-degree relative.addressed ARs, and the role of the inclusion of in-
dividuals with Lynch syndrome was not investigated.
In this meta-analysis we showed that the RR of
developing CRC was almost tripled for individuals with
at least 2 FDRs with CRC, and for individuals with a FDR
with a CRC diagnosed at younger than the age of 50 a 3
to 4 times higher pooled risk was reported compared
with the general population. In contrast, for individuals
with 1 FDR, at least 1 FDR, or a FDR with CRC diagnosed
at older than age 50, the risk of developing CRC wasears in (A) Western Europe and (B) the United States. CRC,
2664 Roos et al Clinical Gastroenterology and Hepatology Vol. 17, No. 13limited with a RR of approximately 2 and a cumulative
AR estimate at age 85 years of less than 5%. Further-
more, we also showed just a slight increase in risk when
having a SDR or TDR with CRC. Comparison of ARs
showed that significantly increased risk starts at the age
of 50 among FDRs, in contrast to previous reports that
justified starting screening at age 40 years in people with
family members with FCC.21
Because of the wide variation in CRC risk among
individuals with a FH of CRC, it might be important to
set a definition of FCC and define who should be
screened more intensively. In addition, a certain level of
increased RR or AR could contribute to justifying more
intensive strategies. AR and 10-year risk estimates
provide better insight of an individual’s risk,82 but vary
widely in the world.1 On the other hand, since fecal
immunochemical testing (FIT)-based population
screening programs have been implemented, FIT also
has been evaluated for individuals with a FH of CRC.
Quintero et al83 showed the equivalence of repeated FIT
screening annually during 3 years and colonoscopy in
FDRs of patients with CRC to detect advanced neoplasia.
Moreover, a recent systematic review showed that FIT
performance in individuals with a FH of CRC was
comparable with the performance in the average-risk
population, reporting high diagnostic accuracy for CRC
but moderate accuracy for advanced neoplasia.84
Therefore, it is important to define which individuals
are at a specific high risk, justifying a change in pre-
ventive measures toward specific colonoscopy surveil-
lance. Nevertheless, future studies and policy makers,
considering uptake of screening as well as diagnostic
accuracy and costs, should better define for which in-
dividuals with a FH of CRC that FIT screening may
replace colonoscopy surveillance. This systematic re-
view and meta-analysis, showing both RRs and ARs,
therefore may harbor a basis for this discussion.
Some limitations of our study need to be mentioned.
Data on CRC risk for those individuals with at least 1 SDR
or TDR were limited, as were cohort studies on CRC risk
with 1 FDR and at least 2 FDRs. Furthermore, because of
the limited number of studies reporting the age at diag-
nosis, we were not able to calculate the RR per increased
unit of age. As a result, multivariable modeling using the
number of relatives affected as well as age at diagnosis and
age of the proband to make more refined considerations
was not possible. ARs are representative for Western
Europe and the United States, but can be extrapolated to
other parts of the world using specific CRC incidence and
all-cause mortality data. We did not address the presence
of having a FH of adenomas despite current surveillance
recommendations according to different clinical practice
guidelines.5–7 Imperiale and Ransohoff85 conducted a
systematic review on the CRC risk of individuals with a
positive FH for adenomas and finally selected only 2
relevant studies. They concluded that there is an increased
risk for CRC, however, those 2 studies harbored limitations
regarding generalizability and validity. In concordancewith this limited available data, the US Preventive Services
Task Force recently made the recommendation not to
perform more intensive surveillance for individuals with
FDRs with adenomas.86
This review had several strengths. First, we reported a
subgroup analysis per study design. Because cohort
studies are less likely to contain bias, we considered these
studies to produce estimates closer to the truth. We also
provided AR estimates for Western Europe and the United
States, which may be used to justify colonoscopy surveil-
lance at a certain risk level. Furthermore, we showed in the
sensitivity analysis that the influence of possible inclusion
of Lynch syndrome patients did not change our overall
estimates. This is most likely because Lynch syndrome
only occurs in 2% to 3% of all CRC cases and therefore has
little contribution to the overall risk estimates.2 Finally, we
reported data about SDRs and TDRs, which is important
information for determining which individuals with FH of
FCC are at a specific high risk.
In summary, we showed that the risk of developing
CRC in individuals with a FH of CRC is lower than ex-
pected, especially according to cohort studies. In-
dividuals with 2 or more FDRs with CRC or a FDR with
CRC diagnosed before the age of 50 were at particularly
increased risk because their RR almost tripled compared
with the general population. Our RR estimates and AR
estimates might be used to identify high-risk groups in
whom specific surveillance strategies aimed to prevent
CRC could be considered. In contrast, the risk of devel-
oping CRC for individuals with a less extensive FH lead to
lower risk estimates and, for these individuals, average-
risk screening programs might be considered an
optimal method for CRC prevention.Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at https://doi.org/10.1016/j.cgh.2019.09.007.References
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MED ("Family"[Mesh] OR famil*[tiab] AND (aggregation[tiab]) OR (("Family"[Mesh] OR famil*[tiab]) AND history[tiab])
OR first degree[tiab] OR second degree[tiab] OR family member[tiab] OR pedigree[tiab])
3661
("Colorectal Neoplasms"[Mesh] OR (colorectal[tiab] OR colonic[tiab] OR rectal[tiab] OR colon[tiab] OR rectum[tiab]
OR anal[tiab] OR anus[tiab]) AND ("Neoplasms"[Mesh] OR "Carcinoma"[Mesh] OR "Adenocarcinoma"[Mesh]
OR neoplas*[tiab] OR tumor* [tiab] OR tumour*[tiab] OR cancer*[tiab] OR carcinoma*[tiab] OR adenocarcinoma*
[tiab]))
("Risk"[Mesh] OR "Incidence"[Mesh] OR "Mortality"[Mesh] OR risk*[tiab] OR incidence[tiab] OR mortality[tiab]
OR "Prevalence"[Mesh] OR "Survival"[Mesh] OR prevalence[tiab] OR survival[tiab])
BASE (exp family/ OR famil*.ti,ab,kw.) AND (aggregation or history).ti,ab,kw.) OR (first degree or second degree
or family member or pedigree).ti,ab,kw.
3863
(exp risk/) OR (exp incidence/) OR (exp mortality/) OR ((risk* or incidence or mortality).ti,ab,kw.)
(exp colorectal tumor/) OR ((colorectal or colonic or rectal or colon or rectum or anal or anus).ti,ab,kw.) AND
((exp neoplasm/) OR ((exp carcinoma/) OR (exp adenocarcinoma/) OR (neoplas* or tumor* or tumour* or cancer*
or carcinoma* or adenocarcinoma*).ti,ab,kw.))
CHRANE (([Family] OR famil*:ti,ab,kw) AND aggregation:ti,ab,kw) OR (([Family] OR famil*:ti,ab,kw) AND history:ti,ab,kw)
OR first degree or second degree or family member or pedigree:ti,ab,kw
303
[Colorectal Neoplasms] OR ([Neoplasms] OR [Carcinoma] OR [Adenocarcinoma] OR neoplas* or tumor* or tumour*
or cancer*
or carcinoma* or adenocarcinoma*:ti,ab,kw) AND (colorectal or colonic or rectal or colon or rectum or anal
or anus:ti,ab,kw)
[Risk] OR [Incidence] OR [Mortality] OR [Prevalence] OR [Survival] OR risk* or incidence or mortality or prevalence
or survival:ti,ab,kw
Supplementary
Figure 1. Forest plot de-
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Supplementary Figure 2. (A) Funnel plot type of family history. (B) Funnel plot type of family history excluding Lynch syn-
drome. FDR, first-degree relative; RR, relative risk; SDR, second-degree relative; TDR, third-degree relative.
Supplementary Figure 3. Funnel plot age at diagnosis of
index case. FDR, first-degree relative. Supplementary Figure 4. Risk of bias graph.
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Supplementary Figure 5. Risk of bias summary table.
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Supplementary Table 1. All-Cause Mortality and Colorectal
Cancer Incidence Data on Which


























aData are from the World Health Organization.15
bData are from Globocan.14
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Supplementary Table 2. Summary of Cohorts and Cross-Sectional Studies Included in the Analysis













of relatives Control group Design
Family history
assessment
Andrieu et al17 2003 France 1993–1998 25–95 NS 117,407 766 5223 Population-based R Registry
Carstensen et al18 1996 Denmark 1982–1992 <60 NS 222,634 1470 5938 Population-based R Registry
Chen et al19 2016 Taiwan 1994–2007 20 244,545/268,738 3,793,565 513,283 16,109 Screening-based P Questionnaire
Frank et al20 2014 Sweden 1958–2010 NS NS 322,923 8,148,737 285,907 Cancer database R Registry
Fuchs et al21 1994 United States 1986–1992 40–75 32,085 176,093 32,085 3007 Population-based P Questionnaire
Fuchs et al21 1994 United States 1982–1990 30–55 87,031 663,936 87,031 8727 Population-based P Questionnaire
Goldgar et al22 1994 United States 1952–1992 All NS NS 4010 28,922 Population-based R Registry
Jenkins et al23 2002 Australia 1992–1996 18–45 NS 120,409 131 2005 Population-based R Registry
Johns et al24 2002 United Kingdom 1976–1978 <55 NS NS 205 NS Population-based R Medical reports
Karner-Hanusch et al25 1997 Austria NS 26–90 NS NS 100 NS Population-based R Registry
Lautrup et al26 2015 Denmark 1995–1998 NS NS 517,219 1200 4182 Population-based P Medical reports
Macklin et al27 1960 United States 1952–1955 NS NS NS 145 1369 Population-based R Questionnaire
Samadder et al28 2014 United States 1980–2010 22–93 9947/8835 NS 18,782 NS Population-based R Registry
Sandhu et al29 2001 United Kingdom 1993–1997 45–74 13,663/16,690 30,202 30,353 NS Population-based CS Questionnaire
Schoen et al30 2015 United States 1993–2001 55–74 70,669/74,100 1,588,477 144,769 NS Screening-based P Questionnaire
Stefansson et al31 2006 Iceland 1955–2000 NS NS 526,345 2770 23,272 Population-based R Registry
Taylor et al32 2010 Australia 2006–2008 45 NS NS 2,327,327 NS Population-based P NS
Tsai et al33 2012 United States 2005–2006 40–89 2057/2910 NS 4967 NS Population-based P Medical reports
Weber-Stadelmann et al34 1990 Switzerland 1982–1988 28–92 100/84 NS 184 1184 Population-based R Medical reports
Wei et al35 2004 United States 1986–2000 40–75 46,632 NS 46,632 3947 Population-based P Questionnaire
Wei et al35 2004 United States 1976–2000 30–55 87,733 NS 87,733 6901 Population-based P Questionnaire
Zeegers et al36 2008 The Netherlands 1986–1999 55–69 58,279/62,573 NS 120,852 NS Population-based P Questionnaire

















Supplementary Table 3. Summary of Case–Control Studies Included in the Analysis
Study Year Place Date
Age of
participants, y Male/female ratio Cases, n Controls, n Control group
Family history
assessment




24–87 NS 286 286 Hospital-based Registry
Bener et al38 2010 Qatar 2008–2009 Cases: 18–82
Controls:
19–80
249/179 146 282 Primary health care centers Questionnaire
Bonelli et al39 1988 Italy 1980–1986 Cases: 25–91
Controls: 24–93
661/608 414 855 Hospital-based Questionnaire
Boutron et al40 1995 France 1985–1990 30–79 NS 171 309 Population-based Questionnaire
Brauer et al41 2002 Canada 1993–1996 40–79 114/497 329 282 Population-based Questionnaire
Centonze et al42 1993 Italy 1987–1989 Mean, 65.9 130/108 119 119 Population-based Questionnaire
Coogan et al43 2000 United States 1983–1996 <70 NS 1330 9653 Hospital-based Questionnaire
Coogan et al43 2000 United States NS 20–69 NS 1006 1090 Population-based Questionnaire
Cotterchio et al44 2005 Canada 1997–2000 20–74 1542/1373 971 1944 Population-based Questionnaire
Cox et al45 2011 New Zealand 2007 30–69 572/555 562 571 Population-based Questionnaire
Duncan et al46 1982 United Kingdom 1981 NS NS 50 50 Hospital-based Medical records
Emami et al47 2015 Iran NS NS NS 200 256 Population-based Questionnaire
Erlinger et al48 2004 United States 1989–2000 >18 230/284 172 342 Population-based Questionnaire
Fatemi et al49 2010 Iran NS NS NS 489 249 Population-based Questionnaire
Fisher et al50 1989 Australia 1975–1984 30–80 NS 146 124 Hospital-based Medical records
Freedman et al51 1996 United States 1982–1993 34–84 NS 163 326 Hospital-based Questionnaire
Ho et al52 2006 China 1998–2000 NS NS 822 926 Hospital-based Questionnaire
Kakourou et al53 2015 United States 1989–2000 >45 231/287 173 345 Population-based Questionnaire
Kim et al54 2009 Korea 2001–2004 30–79 630/474 596 509 Hospital-based Questionnaire
Kotake et al55 1995 Japan 1992–1994 NS NS 363 363 Hospital-based Questionnaire
Kune et al56 1989 Australia 1980–1981 NS NS 702 710 Population-based Questionnaire
La Vecchia et al57 1992 Italy 1985–1991 <75 1694/1304 1222 1766 Hospital-based Questionnaire
Le Marchand et al58 1996 United States 1987–1991 84 1396/988 1192 1192 Population-based Questionnaire
Lilla et al59 2006 Germany 2003–2004 30–94 635/474 505 604 Population-based Questionnaire
Maire et al60 1984 France 1979–1983 20–87 NS 170 170 Hospital-based Questionnaire
Martinez et al61 1979 Puerto Rico 1973–1975 20 253/208 461 461 Population-based Questionnaire
Minami et al62 2003 Japan 1997–2001 40 288/200 488 2444 Hospital-based Questionnaire
Mitchell et al63 2004 United Kingdom NS NS NS 199 133 Population-based Questionnaire
Modica et al64 1995 Italy 1984–1986 NS NS 389 389 Population-based Questionnaire
Modica et al65 1995 Italy 1988–1990 NS NS 213 213 Population-based Questionnaire
Negri et al65 1998 Italy 1992–1996 23–74 3198/2909 1953 4154 Hospital-based Questionnaire
Park et al66 2016 Korea 2007–2014 NS 1875/894 923 1846 Population-based Questionnaire
Peppone et al67 2010 United States 1982–1998 Cases: 40–88
Controls: 40–86
2032/1577 1203 2406 Hospital-based Questionnaire
Pickle et al68 1984 United States 1970–1977 NS 129/133 86 176 Hospital-based Medical records
Pou et al69 2012 Argentina 2006–2010 NS NS 41 95 Hospital-based Questionnaire



















Rosato et al71 2013 Italy and
Switzerland
1985–2009 45 903/787 329 1361 Hospital-based Questionnaire
Safaee et al72 2010 Iran NS NS 426/360 393 393 Population-based Questionnaire
Samadder et al73 2015 United States 1980–2010 NS 105,335/94,425 18,208 181,552 Population-based Questionnaire
Seow et al74 2002 Singapore 1999–2000 20 145/198 121 222 Population-based Questionnaire
Slattery et al75 2003 United States 1991–1994
1997–2001
30–79 2833/2214 2298 2749 Population-based Questionnaire
St John et al76 1993 Australia 1952–1985 NS NS 523 523 Hospital-based Medical records
Weigl et al77 2016 Germany 2003–2014 >30 4512/2954 4313 3153 Population-based Questionnaire


















Supplementary Table 4. Risk of Bias Legend
Domains Rating Prompting items for consideration
Study participation High bias No description of the source population using a baseline table
Low bias Adequately described source population, inclusion and exclusion criteria, and baseline table
No or small nonsignificant differences in participants and nonparticipants are accounted for in the analysis
Study attrition High bias >20% Loss to follow-up evaluation owing to prognostic factors related to the outcome
Low bias <20% Loss to follow-up evaluation owing to prognostic factors related to the outcome
Prognostic factor measurement High bias The family history was not assessed for the control group or nothing was mentioned about the collection of data on family history
Family history was assessed by questionnaire without verification
Low bias Family history was assessed by interview/questionnaire with verification using medical records/histology reports
Outcome measurement High bias Method of outcome measurement is different for cases and control groups, or no verification of outcome at all
Low bias Colorectal cancer based on questionnaire data and verification through medical records/histology, data were analyzed per subgroup of
method of verification
Study confounding High bias Family history estimate is not part of the primary analysis and therefore not adjusted for confounders
No adjustment or unequal distribution
Low bias Matching or adjustment for multiple relevant confounders
Statistical analysis and reporting High bias Family history estimate is not part of the primary analysis and therefore was not discussed in the statistical analysis of the methods
Only a multivariate model was reported without explanation about how this was conducted
Reported only summary estimates without raw data
Low bias Adjustment for factors prespecified in statistical analysis, raw data present
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